Search
Close this search box.

Regeneron’s gene therapy triumphs twice, restoring hearing in children

Regeneron Pharmaceuticals’ gene therapy for otoferlin hearing loss, DB-OTO, has restored hearing to normal in an 11-month-old child within 24 weeks and improved hearing in another four-year-old child at six weeks.

The data is from an open-label Phase I/II CHORD trial (NCT05788536), which was presented at the 2024 American Society of Gene and Cell Therapy (ASGCT) annual conference taking place in Baltimore from 7 to 11 May.

As part of the CHORD study, both children received a single intracochlear injection of DB-OTO in one ear. The trial’s secondary endpoints include hearing improvement, measured using auditory brainstem response (ABR) and behavioural audiometry with pure-tone audiometry (PTA).

At 24 weeks, the younger child observed improvement of hearing to normal levels, with an average 80 decibels (dB) improvement from baseline. The second participant observed an average 16dB improvement in hearing response, compared to baseline, at six weeks. The surgical procedure and the gene therapy were well tolerated, with no treatment-related adverse events or serious adverse events.

DB-OTO is an adeno-associated virus gene therapy designed to restore hearing in patients with congenital otoferlin hearing loss. The rare hearing loss is caused by variants in the otoferlin gene that impair the production of the OTOF protein, responsible for communication between the sensory cells of the inner ear and the auditory nerve.

The Phase I/II CHORD trial is still recruiting participants across the US and Europe, according to Regeneron. The study is expected to enrol approximately 22 children with otoferlin hearing loss aged 17 years and younger.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

<!–

–>

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Other companies developing gene therapies for improving otoferlin hearing loss include Sensorion and Akouos. In January, Sensorion received the go-ahead to start Phase I/II clinical trial of its gene therapy SENS-501 for otoferlin hearing loss in select European countries. The study will evaluate SENS-501 in children aged six to 31 months at the time of treatment.

The same month, Eli Lilly and Company subsidiary Akouos shared data from the Phase I/II AK-OTOF-101 clinical trial of its investigational gene therapy, AK-OTOF. The results showed that the adeno-associated virus gene therapy improved hearing in children with otoferlin hearing loss.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

<!– –>